Paul Hudson, Sanofi CEO (Eric Piermont/AFP via Getty Images)

Sanofi in­vests in the fu­ture of mR­NA with plan to pump bil­lions of dol­lars in­to next-gen cell ther­a­py busi­ness

With Mod­er­na and Pfiz­er/BioN­Tech paving the road for mR­NA ther­a­peu­tics, a gold rush is un­der­way across bio­phar­ma to take that promis­ing ba­ton and run with it in­to new dis­ease ar­eas. Now, Sanofi is en­gi­neer­ing an am­bi­tious — and ex­pen­sive —plan to re­tool its R&D ap­proach around mR­NA vac­cines, and it’s lean­ing on a ma­jor re­search pact to help get it there.

Sanofi will in­vest up to $477 mil­lion per year to build out its “end-to-end” in­ter­nal ca­pa­bil­i­ties in mR­NA, the cell ther­a­py tech­nol­o­gy un­der­pin­ning Mod­er­na and Pfiz­er/BioN­Tech’s Covid-19 vac­cines with red-hot po­ten­tial in oth­er dis­eases, the French drug­mak­er said Tues­day.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.